EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Area of Science:

• Oncology
• Clinical Trials
• Surgical Oncology

Background:

• Osteosarcoma is a rare bone cancer requiring effective treatment strategies.
• International collaboration is crucial for rare cancer research.
• Previous studies have explored various chemotherapy regimens for osteosarcoma.

Purpose of the Study:

• To determine the effect of changing post-operative chemotherapy on survival in resectable osteosarcoma.
• To assess the impact of histological response on treatment outcomes.
• To evaluate quality of life in patients undergoing osteosarcoma treatment.

Main Methods:

• A large international study involving two randomized controlled trials in resectable osteosarcoma.
• Patients received pre-operative MAP chemotherapy (cisplatin, doxorubicin, methotrexate).
• Post-operative chemotherapy varied based on histological response (≥10% viable tumor vs. <10%).

Main Results:

• 2260 patients were registered, with 1334 randomized across 17 countries.
• Pre-operative chemotherapy was completed by 94% of patients.
• 50% of patients achieved ≥90% tumor necrosis at surgery.

Conclusions:

• EURAMOS-1 demonstrates the feasibility of international collaboration for rare cancer trials.
• New collaborative models are needed to improve outcomes in rare cancers.
• Significant regulatory, financial, and operational challenges exist for future rare cancer studies.